Alembic Pharma Q2 Review - Weakness In U.S. Outweighs Strength In Domestic Formulation: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Alembic Pharmaceuticals Ltd. delivered in-line Q2 FY22 earnings. Subdued performance in U.S./active pharma ingredient was offset by a better-than-expected show in the domestic formulation segment.
The YoY declining trend in the U.S. business has reached a trough with the limited impact of price erosion and an increased pace of launches going forward.
We lower our FY22E/FY23E earnings per share estimate of Alembic Pharma by 7.5%/5.8%, factoring in:
a delay in successful compliance at injectables sites,
gradual revival in U.S. sales, and
higher raw material/logistics costs
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.